 |
Journal articles
First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients
B. Maucherat
1
A. Leduc-Pennec
2
N. Fleury
3
Ludovic Ferrer
4, 5
E. Bourbouloux
6
H. Simon
7
M. Le Thiec
1
D. Rusu
1
V. Fleury
1
M. Colombie
1
A. Morel
1
Françoise Kraeber-Bodéré
4, 1
Loïc Campion
8, 9
Caroline Rousseau
4, 1
4
CRCINA-ÉQUIPE 13 - Nuclear Oncology
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
8
CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Loïc Campion 8, 9
Author
Caroline Rousseau 4, 1
Author
1
Service de médecine nucléaire [Saint-Herblain] (Boulevard Jacques Monod. 44805 Saint-Herblain - France)
- Centre René Gauducheau (France)
- Institut Régional du Cancer Nantes-Atlantique (IRCNA) (France)
- UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] (15, rue André Boquel - 49055 Angers cedex 02 - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
2
Service de médecine nucléaire [Brest] (2 avenue Foch 29609 Brest Cédex - France)
- Hôpital Morvan [Brest] (2 Av Foch – 29609 Brest Cedex - France)
- CHRU Brest - Centre Hospitalier Régional Universitaire de Brest (France)
3
Délégation à la recherche clinique [CHU Nantes] (France)
- CHU Nantes - Centre hospitalier universitaire de Nantes (1 Place Alexis-Ricordeau, 44000 Nantes - France)
4
CRCINA-ÉQUIPE 13 - Nuclear Oncology (Institut de Recherche en Santé de l'Université de Nantes - 8 quai Moncousu - BP 70721 - 44007 Nantes cedex 1 - France)
- CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (8 quai de Moncousu - BP 70721 - 44007 Nantes Cedex 1 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR1232 (101, rue de Tolbiac, 75013 Paris - France)
- UFR MEDECINE - Université de Nantes - UFR de Médecine et des Techniques Médicales : UMR1232 (1 rue Gaston Veil BP 53508 44035 NANTES Cedex 1 - France)
- UN - Université de Nantes (1, quai de Tourville - BP 13522 - 44035 Nantes cedex 1 - France)
- CHU Nantes - Centre hospitalier universitaire de Nantes : UMR1232 (1 Place Alexis-Ricordeau, 44000 Nantes - France)
- CNRS - Centre National de la Recherche Scientifique : ERL6001 (France)
- UA - Université d'Angers : UMR1232 (Université d'Angers - 40 Rue de Rennes, BP 73532 - 49035 Angers CEDEX 01 - France)
5
Département de Physique [Saint Herblain] (France)
- UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] (15, rue André Boquel - 49055 Angers cedex 02 - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
6
Département d'Oncologie [Saint Herblain] (France)
- UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] (15, rue André Boquel - 49055 Angers cedex 02 - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
7
Département de Radio-Oncologie [CHRU Brest] (France)
8
CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA, INSERM UMR1232,CNRS ERL6001 - IRS-UN 8 Quai Moncousu - BP 70721 - 44007 Nantes Cedex 1 - France)
- CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (8 quai de Moncousu - BP 70721 - 44007 Nantes Cedex 1 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR1232 (101, rue de Tolbiac, 75013 Paris - France)
- UFR MEDECINE - Université de Nantes - UFR de Médecine et des Techniques Médicales : UMR1232 (1 rue Gaston Veil BP 53508 44035 NANTES Cedex 1 - France)
- UN - Université de Nantes (1, quai de Tourville - BP 13522 - 44035 Nantes cedex 1 - France)
- CHU Nantes - Centre hospitalier universitaire de Nantes : UMR1232 (1 Place Alexis-Ricordeau, 44000 Nantes - France)
- CNRS - Centre National de la Recherche Scientifique : ERL6001 (France)
- UA - Université d'Angers : UMR1232 (Université d'Angers - 40 Rue de Rennes, BP 73532 - 49035 Angers CEDEX 01 - France)
9
Unité de Biométrie [ICO, Saint Herblain] (France)
- UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes] (15, rue André Boquel - 49055 Angers cedex 02 - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
Abstract : Aim/Introduction: About 70% of primitive breast cancers had positive estrogen receptors (ER) and may benefit from hormonotherapy. However, ER expression in breast cancer metastases is heterogeneous and about 15% of metastases lost this expression over time. Biopsies were not possible systematically. 16α-18Fluoro-17β-Oestradiol (18FES) is a radiopharmaceutical which predict the response to the first line hormonotherapy. The aim of this prospective study (NCT03442504) was to determine the predictive value of PET at the patient level, before a second line hormonotherapy (2nd- HT) on the FDG response obtained at 6 weeks of treatment. Materials and Methods: We prospectively included 12 ER+ metastatic breast cancer patients, HER2 negative, in progression despite first line hormonotherapy. For the complete study, 60 patients will be included. Due to 2nd-HT proposed by oncologist, we performed 18FES PET-CT (18FES-BL) and 18FDG PET-CT (18FDG-BL) at baseline in the month before the new treatment introduction. Follow-up with 18FDG PET-CT and CT
Document type :
Journal articles
Domain :
Complete list of metadatas
https://www.hal.inserm.fr/inserm-02337440
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, October 29, 2019 - 2:28:28 PM
Last modification on : Sunday, October 25, 2020 - 7:06:29 AM
Long-term archiving on: : Thursday, January 30, 2020 - 8:07:26 PM
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, October 29, 2019 - 2:28:28 PM
Last modification on : Sunday, October 25, 2020 - 7:06:29 AM
Long-term archiving on: : Thursday, January 30, 2020 - 8:07:26 PM
File
OP-284 EANM2019.pdf
Files produced by the author(s)
Identifiers
- HAL Id : inserm-02337440, version 1
Collections
Citation
B. Maucherat, A. Leduc-Pennec, N. Fleury, Ludovic Ferrer, E. Bourbouloux, et al.. First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (1), pp.S117. ⟨inserm-02337440⟩
Metrics
Record views
58
Files downloads